Roche has ramped up its investment in NVIDIA's AI chips, launching an upscaled hybrid-cloud AI factory that it believes is ...

NYSE-listed Alto Neuroscience has raised $120 million in a private placement that will be used to advance its recently ...

BioMarin has suspended dosing in phase 2 trials of its achondroplasia therapy Voxzogo aimed at broadening its label, while it ...

A federal judge has pushed back against attempts by HHS Secretary Robert F Kennedy Jr to overhaul immunisation policy in the ...

AstraZeneca's cancer immunotherapy Imfinzi has been approved in the EU for use before and after surgery for early-stage ...

Rentschler taps biopharma vet to lead ops. Rentschler Biopharma, the German CDMO with offices in Massachusetts and Stevenage, ...

In order to discuss this topic further, pharmaphorum spoke with Sheila Diamond, director of scientific engagement at Medidata ...

Pharmaceutical organisations rarely struggle to write strategy. They struggle to protect it. Global brand teams define ambition precisely. Segmentation models are refined. Launch plans are ...

The analysis – reported at the European Association of Urology (EAU) annual congress in London, UK – shows that it is "no ...

Kerendia has hit the spot in another phase 3 trial that could extend its use as a treatment for patients with chronic kidney ...

The US regulator has cleared its Arexvy RSV shot for adults in that age group who are at increased ​risk of lower respiratory ...

Johnson & Johnson has revealed early clinical data with a new formulation of its FGFR inhibitor erdafitinib that suggests it ...